FDA
-
-
-
-
-
-
-
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
-
-
-
-
-
-
-
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
-
-
-
-
-
-
-
FDA approves high dose SPINRAZA for spinal muscular atrophy
-
-
-
-
-
-
-
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
-
-
-
-
-
-
-
Biogen earnings preview Q4: set for weaker print, Leqembi outlook in focus
-
-
-
-
-
-
-
FDA accepts LEQEMBI IQLIK application for weekly Alzheimer's treatment
-
-
-
-
-
-
-
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 America
-
323,884 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

